MIRA INFORM REPORT

 

Report Date :

24.02.2011

 

IDENTIFICATION DETAILS

 

Correct Name :

SUAN FARMA SOCIEDAD ANONIMA

 

 

Registered Office :

Calle De Einstein, 8, 28108 Alcobendas  Madrid

 

 

Country :

Spain

 

 

Financials (as on) :

31.12.2009

 

 

Date of Incorporation :

01.01.1993

 

 

Legal Form :

Joint Stock Company

 

 

Line of Business :

Wholesaler of pharmaceutical products

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

323.869,00 €

 

 

Status :

Moderate

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – June 30, 2010

 

Country Name

Previous Rating

                   (01.04.2010)                  

Current Rating

(30.06.2010)

Spain

a2

a2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Company name

 

SUAN FARMA SOCIEDAD ANONIMA

TAX NUMBER: A80624067

 

EXECUTIVE SUMMARY

  

Identification

Current Business Name: SUAN FARMA SOCIEDAD ANONIMA

Commercial Name: SUANLAB

Other names:  YES

Current Address:  CALLE DE EINSTEIN, 8

28108 ALCOBENDAS MADRID 

Branches:  4

Telephone number: 913446890 Fax: 913446894

URL:  www.suanfarma.com 

Corporate e-mail:  suanfarma@suanfarma.com

 

Trade Risk

 

Credit Appraisal: 323.869,00 €

Incidents:  YES

R.A.I.:  NO

Bank and business defaults of payment - ASNEF INDUSTRIAL:  NO

 

Financial Information

 

Balance sheet latest sales (2009):  36.236.485,00 € (Trade Register)

Result: 366.931 €

Total Assets: 22.954.145 €

Social Capital:  1.000.050,00 €

Employees:  27

Listed on a Stock Exchange: NO

 

 

Commercial Information

 

Incorporation date:  28/05/1993

Activity:  Wholesale of pharmaceutical products

NACE 2009 CODE: 4646

International Operations:  Imports and Exports

 

Corporate Structure

 

President:

ARA SANZ HECTOR

 

Parent Company:

ARA SANZ HECTOR

 

Participations:  10

 

Other Complementary Information

Latest filed accounts published in the Mercantile Register: 2009

Type of Accounts available at the Mercantile Register: Individuals

Latest act published in BORME:  18/01/2011 Appointments

Latest press article:  30/11/2010 EXPANSIÓN (PRODUCTS AND ACTIVITIES)

Bank Entities:  There are

 

The date when this report was last updated is 21/02/2011.

The information contained in this report has been investigated and contrasted on 21/02/2011

 

Credit Appraisal

 

Maximum Credit

(from 0 to 6,000,000 €)

 

Favourable to 323.869,00 €

 


Financial Situation

Exercise:2009

Treasury

Restrained

Indebtedness

Important

Profitability

Average

Balance

Bad

 

Performance

 

Incidents

None or Negligible

Business Trajectory

Excellent

 

 

INCIDENTS

 

Summary

LEGAL ACTIONS: No legal actions registered

ADMINISTRATIVE CLAIMS: 2  ( Last:22/12/2009 , first: 22/12/2009 )

 

 

 

With the Social Security:

2

 

With the Tax Authorities:

0

 

With Other Official bodies:

0

 

AFFECTED BY: No significant element.

  

Latest Administrative Claims

Figures expressed in €

WITH THE SOCIAL SECURITY.

Notifications

DATE

ORGANIZATION

AMOUNT

22/12/2009

CENTRAL TREASURY FOR SOCIAL SECURITY DIRECCION PROVINCIAL DE TRABAJO Y SEGURIDAD SOCIAL

896,66

22/12/2009

CENTRAL TREASURY FOR SOCIAL SECURITY DIRECCION PROVINCIAL DE TRABAJO Y SEGURIDAD SOCIAL

896,66

There are 2 administrative claims with the Social Security registered

  

Detail of the Latest Administrative Claims

Figures expressed in €

Notifications

WITH THE SOCIAL SECURITY.

Phase: DEBTS WITH OFFICIAL BODIES

Organization: CENTRAL TREASURY FOR SOCIAL SECURITY DIRECCION PROVINCIAL DE TRABAJO Y SEGURIDAD SOCIAL

Concept: Share

Date of the claim: 22/12/2009

Period: 0309 0309

Source: Published in the Gazette of MADRID Appendix 01, on 22/12/2009, page 3

Amount: 896,66

Figures expressed in €

Notifications

WITH THE SOCIAL SECURITY.

Phase: DEBTS WITH OFFICIAL BODIES

Organization: CENTRAL TREASURY FOR SOCIAL SECURITY DIRECCION PROVINCIAL DE TRABAJO Y SEGURIDAD SOCIAL

Concept: Share

Date of the claim: 22/12/2009

Period: 0409 0409

Source: Published in the Gazette of MADRID Appendix 01, on 22/12/2009, page 3

Amount: 896,66

 

BANK AND BUSINESS DEFAULTS OF PAYMENT - ASNEF INDUSTRIAL

 

 

 

R.A.I.

  

COMPANY NOT REGISTERED IN THE R.A.I.

This company is not registered in the Disputed Bills register (R.A.I.)

DATE AND TIME OF THE CONSULTATION

15/02/2011 09:02:26

Information from the Registro de Aceptaciones Impagados (RAI)- Disputed Bills register.

It can only be used for information legitimate needs of the consulting party, in accordance with its social or business activity, in order to grant a credit or the monitoring or control of the already granted credits and can not be transmitted or communicated to thirds, nor copied, duplicated, reproduced nor implemented to any database , owned or external, or reused it in anyway, direct or indirectly.

 

FINANCIAL ELEMENTS AND SECTORIAL COMPARATIVE

  

FINANCIAL ELEMENTS

 

The shaded amounts in the following financial statements have been converted to the norms established in the PGC2007 derived from RD 1514/2007 and 1515/2007, this way comparatives could be shown with the amounts of exercises initiated from 1/01/08.

 

Balance-sheet analysis

Figures given in €

 

31/12/2009

(12)

BALANCE SHEET

 

%

ASSETS

 

31/12/2008

(12)

BALANCE SHEET

 

%

ASSETS

 

31/12/2007

(12)

BALANCE SHEET

 

%

ASSETS

 

ASSETS

 

 

 

 

 

 

A) NON CURRENT ASSETS

8.675.293,00

37,79

5.659.138,00

29,30

5.221.652,16

28,51

B) CURRENT ASSETS

14.278.852,00

62,21

13.657.458,00

70,70

13.093.359,46

71,49

LIABILITIES

 

 

 

 

 

 

A) NET WORTH

3.383.852,00

14,74

3.472.700,00

17,98

3.804.649,79

20,77

B) NON CURRENT LIABILITIES

4.943.622,00

21,54

1.980.433,00

10,25

2.782.714,60

15,19

C) CURRENT LIABILITIES

14.626.671,00

63,72

13.863.463,00

71,77

11.727.647,23

64,03

 

Profit and Loss Account Analysis

Figures given in €

 

31/12/2009

(12)

BALANCE SHEET

 

% NET TURNOVER

 

31/12/2008

(12)

BALANCE SHEET

 

% NET TURNOVER

 

31/12/2007

(12)

BALANCE SHEET

 

% NET TURNOVER

 

SALES

36.236.485,00

 

33.234.919,00

 

33.938.992,32

 

GROSS MARGIN

6.551.722,00

18,08

6.727.623,00

20,24

6.242.994,02

18,39

EBITDA

359.692,00

0,99

530.900,00

1,60

487.888,28

1,44

EBIT

339.847,00

0,94

603.860,00

1,82

320.879,14

0,95

NET RESULT

366.931,00

1,01

565.733,00

1,70

455.603,26

1,34

EFFECTIVE TAX RATE (%)

18,11

 

11,32

 

21,38

 

 

 

COMPARATIVE SECTOR ANALYSIS

 

 Values table

Figures expressed in %

 

COMPANY

(2009)

 

SECTOR

DIFFERENCE

BALANCE SHEET ANALYSIS: % on the total assets

 

 

 

ASSETS

 

 

 

A) NON CURRENT ASSETS

37,79

22,56

15,24

A) CURRENT ASSETS

62,21

77,44

-15,24

LIABILITIES

 

 

 

A) NET WORTH

14,74

41,22

-26,48

B) NON CURRENT LIABILITIES

21,54

8,37

13,17

C) CURRENT LIABILITIES

63,72

50,42

13,31

 

 

 

 

 

COMPANY

(2009)

 

SECTOR

DIFFERENCE

PROFIT AND LOSS ACCOUNT ANALYSIS: % on the total operating income

 

 

 

SALES

99,79

98,58

1,21

GROSS MARGIN

18,04

34,83

-16,78

EBITDA

0,99

6,62

-5,63

EBIT

0,94

4,87

-3,93

NET RESULT

1,01

3,59

-2,58

 

 

Sector Composition

Compared sector (NACE 2009): 4646

Number of companies: 112

Size (Sales Figure): 7,000,000.00 - 40,000,000.00 Euros

 

 

OTHER DATA FROM THE ANNUAL FINANCIAL REPORT

  

Results Distribution

Source: annual financial report 2009

Figures given in €

DISTRIBUTION BASE

APPLICATION A

Profit and Loss Account Balance

366.930,64

Legal Reserve

0,00

Carry over

0,00

Goodwill reserve

0,00

Voluntary reserves

0,00

Special reserves

0,00

Other reserves disposable at will

0,00

Voluntary reserves

166.930,64

Total of Amounts to be distributed

366.930,64

Dividends

200.000,00

 

 

Carry over and others

0,00

 

 

Compensation of previous exercises losses

0,00

 

 

Application total

366.930,64

 Auditing

Source: filing of annual financial statement 2009

Auditors’ opinion: FAVOURABLE

Auditor: ATTEST SERVICIOS EMPRESARIALES S.L.

Auditing fees: 18.700,00 €

 

Facts subsequent to the closing

Source: Annual financial report 2009

Ya con efectos primero de Enero de 2010, se ha producido el nombramiento de D. Francisco Fernández que venía desempeñando las funciones de Director Comercial desde el año 2006 como Director General, pasando D. Miguel Ara, que ha dirigido la empresa desde el año 1999, a desempeñar las funciones de Director General del Grupo Suanfarma, puesto de nueva creación

 

company ADDRESSES

  

Business address

Current Legal Seat Address: 

CALLE DE EINSTEIN, 8

28108 ALCOBENDAS  MADRID

Previous Seat Address: 

CALLE ISABEL COLBRAND 10 - 3 PLT OF 113 114

28050 MADRID

 

Branches

STREET

POSTAL CODE

TOWN

PROVINCE

CALLE TORREBLANCA, 10

08970

SANT JOAN DESPI

Barcelona

CALLE BRAVO MURILLO, 377

28020

MADRID

Madrid

CALLE FERNAN GONZALEZ, 56

28009

MADRID

Madrid

CALLE SAN ROQUE, 12

28140

FUENTE EL SAZ DE JARAMA

Madrid

There are 4 branches registered

 

 

CORPORATE STRUCTURE

  

ADMINISTRATIVE LINKS

 

Main Board members, Directors and Auditor

POSITION

NAME AND SURNAME

APPOINTMENT DATE

PRESIDENT

ARA SANZ HECTOR

10/12/2010

VICE-PRESIDENT

FERNANDEZ FUSTER MANUEL

10/12/2010

MEMBER OF THE BOARD

ARA PARGA MIGUEL

10/12/2010

 AUDITOR

APPOINTMENT DATE

ATTEST SERVICIOS EMPRESARIALES SLP

11/02/2010

 

There are 4 board members, directors and auditors registered

 

In case you need more information you can request:Board Members Monitoring

Board members remuneration

Source: Annual financial report 2009

Board members remuneration: 0,00 €

 Functional Managers

POSITION

NAME AND SURNAME

General Manager

ARA PARGA MIGUEL

Financial Director

VIDAL RODRIGUEZ LUIS

Human Resources Director

VIDA LUIS

 

 

FINANCIAL LINKS 

 

Direct Shareholders

 

BUSINESS NAME

CIF / COUNTRY

%

SOURCE

DATE REP.

 

ARA SANZ HECTOR

 

80,00

OWN SOURCES

15/07/2010

 

FERNANDEZ FUSTER MANUEL

 

10,00

OWN SOURCES

15/07/2010

 

ARA PRAGA MIGUEL

 

10,00

OWN SOURCES

15/07/2010

There are 3 direct financial links through shareholders registered

 

Former Shareholders

 

BUSINESS NAME

CIF / COUNTRY

%

SOURCE

DATE REP.

 

ARA SANZ IGNACIO

 

5,00

TRADE REG.

15/07/2010

 

Direct Participations

 

BUSINESS NAME

CIF / COUNTRY

%

SOURCE

DATE REP.

 

LABOSUAN INVESTIGACION Y DESARROLLO SL.

B86105459

100,00

B.O.R.M.E.

21/01/2011

 

INMUEBLES SUANFARMA SL.

B86105426

100,00

B.O.R.M.E.

28/01/2011

 

PLANTAS MEDICINALES DE CATALUNA SA

A60386539

80,00

OWN SOURCES

21/02/2011

 

SUAN FARMA C A

 

80,00

TRADE REG.

31/12/2009

 

SUAN FARMA INC

UNITED STATES

80,00

TRADE REG.

31/12/2009

 

ALBERTO GIRONELLA, S.A. DE C.V.

MEXICO

69,97

TRADE REG.

31/12/2009

 

TORREFARMA S.L.

B83346122

50,00

OWN SOURCES

21/02/2011

 

ANGEL BIOTECHNOLOGY LTD

UNITED KINGDOM

3,40

OWN SOURCES

21/02/2011

 

BIOSEARCH SA

A18550111

0,33

TRADE REG.

31/12/2008

 

SUANFARMA BIOTECH S.G.E.C.R. S.A.

A85184703

Indef.

OWN SOURCES

21/02/2011

 

Former Participations

 

BUSINESS NAME

CIF / COUNTRY

%

SOURCE

DATE REP.

 

FARMAPROJECTS, SA

A58692997

30,00

TRADE REG.

31/12/1996

 

3 P BIOPHARMACEUTICALS S.L.

B31875800

6,79

TRADE REG.

31/12/2007

 

EXXENTIA GRUPO FITOTERAPEUTICO S.A. (EXTINGUIDA)

A81166258

3,00

EL ECONOMISTA

24/01/2008

Company with rating inferior to 7

 

 

POTENTIAL LINKS

 

Search for Link by Administrator

Search Criterion: ”ARA SANZ HECTOR “

COMPANY

POSITION

PROVINCE

SUANFARMA BIOTECH S.G.E.C.R. S.A.

Presidente

 

MADRID

 

IBERSUAN S.L.

Presidente

 

MADRID

 

BIOANTIEDAD S.A.

Presidente

 

MADRID

 

INMUEBLES SUANFARMA SL.

Presidente

 

MADRID

 

DISTRIMSA SA

Presidente

 

MADRID

 

In case you need more information you can request:Board Members Monitoring

  

Name Search in the Internet

Search Criterion: ”SUAN FARMA SOCIEDAD ANONIMA”

URL: www.suanfarma.com

SUANFARMA S.A. Comercializa y distribuye materias primas para la ...  comercializa y distribuye intermedios y materias primas para la industria farmacéutica y veterinaria en todo el mundo.

URL: www.suanfarma.com

SUANFARMA S.A.  SUAN FARMA, S.A. | Einstein, 8 · 28108 Alcobendas · Madrid · España Tlf ...

URL: www.suanfarma.com

SUANFARMA SA  SUAN FARMA, S.A. markets and distributes active pharmaceutical ingredient ...

URL: www.suanfarma.com

Suan Farma, S.A. comercializa y distribuye intermedios y materias ...  SUAN FARMA, S.A. is a private Spanish company founded in 1993. The company ...

URL: www.suanfarmabiotech.com

socios - SUANFARMA Biotech  SUANFARMA, SA (1993), dedicada al comercialización de materias primas para el sector de medicamentos genéricos para la industria farmacéutica y veterinaria. ...

 

CREDIT INFORMATION

 

Constitution

Incorporation date: 28/05/1993

 

Origin / Foundation

Establishment date: 01/01/1993

Founder’s Name: LA TITULAR ES FUNDADORA INICIAL DEL NEGOCIO

 

Activity

Activity: Wholesale of pharmaceutical products

NACE 2009 CODE: 4646

NACE 2009 Activity: Wholesale of pharmaceutical goods

Business: IMPORTACION, EXPORTACION Y COMPRAVENTA AL POR MAYOR Y AL POR MENOR DE PRODUCTOS QUIMICOS FARMACEUTICOS Y ESPECIALIDADES PARA USOS HUMANO Y VETERINARIO.

Activity description: COMERCIALIZACION Y DISTRIBUCION DE PRINCIPIOS ACTIVOS FARMACEUTICOS PARA USO HUMANO Y VETERINARIO.

 

Employees

Latest employees figure: 27 (2010)

% of fixed employees: 100,00%

% of men: 59,38%

% of women: 40,62%

 


Employees evolution

 

 

 

 Employees distribution

Source: Annual financial report 2009

CATEGORY

AVERAGE NUMBER OF EMPLOYEES

MEN

WOMEN

Distribution by sexes

 

19

13

 

COMMERCIAL OPERATIONS

 

PURCHASES

Imports from: TODO EL MUNDO

SALES

Exports to: TODO EL MUNDO

 

SUPPLIERS

BUSINESS NAME

INTERNATIONAL

SUAN FARMA INC

YES

TORREFARMA S.L.

NO

SUAN FARMA BITECH S.C.G.R.

YES

SUAN FARMA SA

NO

PLAMECA SL

NO

There are 5 Suppliers

 

CLIENTS

BUSINESS NAME

INTERNATIONAL

PLAMECA SL

NO

SUAN FARMA BIOTECH S.C.G.R.

YES

TORREFARMA S.L.

NO

SUAN FARMA INC

YES

SUAN FARMA C.A.

YES

There are 5 Clients

 

Professional and advertising services

Source: Annual financial report 2009

Professional services expenses: 1.798.268,00 €

Advertising services expenses: 204.648,00 €

 

Banks

ENTITY

BRANCH

ADDRESS

TOWN OR CITY

PROVINCE

BANKINTER, S.A.

9400

AVDA. BRUSELAS, 12

ALCOBENDAS

Madrid

BANCO ESPAÑOL DE CREDITO, S.A.

 

 

MADRID

 

BANCO PASTOR, S.A.

 

 

MADRID

 

DEUTSCHE BANK, S.A.E.

 

 

MADRID

 

BANCO SANTANDER, S.A.

 

 

MADRID

 

There are 10 bank entities registered

 

 

Summary of bank operations

Discount facilities: 0

Credit policy: 1

Mortgage loan: 0

Loans with no real security: 0

 


Bank operations

 

 Debt type: Credit policy

Granted limit:400.000,00 €

 Used limit:300.439,00 €

 Available limit:99.561,00 €

 Source: Filed Accounts (2009)

 

 

There are 1 bank operations registered

 

Brands

 

FORMER NAMES: 

          FLAVINE ESPANA SOCIEDAD ANONIMA.

Brand name: DEO-NATURAL (Valid)

Type: JOINT    Scope: NATIONAL    Date: 15/11/2002

Name: SUANLAB (Valid)

Type: DENOMINATIVE    Scope: NATIONAL    Date: 17/03/2009

Name: LABOSUAN (Valid)

Type: DENOMINATIVE    Scope: NATIONAL    Date: 17/03/2009

Name: SUANFARMA (Valid)

Type: DENOMINATIVE    Scope: NATIONAL    Date: 21/03/2006

Name: SUANFARMA BIOTECH (Valid)

Type: DENOMINATIVE    Scope: NATIONAL    Date: 16/03/2006

There are 6 brands, signs and commercial names

 

 


LEGAL STRUCTURE

  

Constitution Data

Register Date: 28/05/1993

Register town: Madrid

Announcement number: 262754

 

Current structure data

Legal form: Joint-stock Company

Social Capital: 1.000.050,00 €

Paid-up capital: 1.000.050,00 €

 

Legal Aspects

Obligation to fill in Financial Statements: YES

Chamber census: YES (2009)

 

 

B.O.R.M.E.

(OFFICIAL COMPANIES REGISTRY GAZETTE)

 

Summary

·         Acts on activity: 0

·         Acts on administrators: 19 (Last: 18/01/2011, first: 20/07/1993)

·         Acts on capital: 2 (Last: 14/11/2007, first: 14/11/2007)

·         Acts on creation: 1 (Last: 20/07/1993)

·         Acts on filed accounts: 24 (Last: 01/12/2010, first: 25/07/1995)

·         Acts on identification: 3 (Last: 12/02/2010, first: 12/11/1996)

·         Acts on Information: 3 (Last: 24/02/1997, first: 12/11/1996) 

 

Latest acts in B.O.R.M.E.

Other acts

ACT

DATE

NOTICE NUM.

TRADE REGISTER

Appointments

18/01/2011

18268

Madrid

Re-elections

10/12/2010

454985

Madrid

Resignations

10/11/2010

413914

Madrid

Appointments

15/04/2010

150410

Madrid

Change of registered address

12/02/2010

61486

Madrid

Appointments

11/02/2010

59919

Madrid

Capital enlargement

14/11/2007

561018

Madrid

Capital enlargement

14/11/2007

561018

Madrid

 

Latest filed accounts

ACT

DATE

NOTICE NUM.

TRADE REGISTER

Annual Filed Accounts (2009)

01/12/2010

1117903

Madrid

Annual Filed Accounts (2009) consolidated

19/11/2010

1062189

Madrid

Annual Filed Accounts (2008) consolidated

18/11/2009

873226

Madrid

There are 52 acts registered

 

PRESS ARTICLES

 

Press summary by type of information (last five years)

Legal notices: 1 (Last: 22/01/2010)

Structural Data: 3 (Last: 19/09/2007, first: 27/01/2006)

Informative data: 1 (Last: 27/11/2009)

Financial Information: 0

Negative information: 0

Business lines: 3 (Last: 30/11/2010, first: 08/09/2006)

Historical press releases: 6 (Last: 05/05/2005, first: 22/07/1995)

 

Latest press article published

 30/11/2010 EXPANSIÓN (Page 16) PRODUCTS AND ACTIVITIES

SUANFARMA prepara su segundo fondo de capital riesgo, con el que espera levantar alrededor de 40 millones de euros para invertir en pymes innovadoras de base biotecnológica. La gestora cerrará en los próximos días el tramo institucional, que podría llegar a los 15 millones de euros.  

SUANFARMA nació en la industria de los medicamentos genéricos, como fabricante y proveedor de principios activos para laboratorios. En su apuesta por la diversificación, la empresa puso en marcha una incubadora de pequeñas y medianas empresas innovadoras.  

Para solventar el problema de la financiación, el grupo creó una gestora y levantó un primer fondo de 9 millones de euros en 2007. 

 

 22/01/2010 EXPANSIÓN - LEGAL ANNOUNCEMENTS

LA JUNTA GRAL. EXTRAORDINARIA Y UNIVERSAL DE ESTA SDAD., CELEBRADA EL DIA 22/12/09, ACORDO TRASLADAR EL DOMICILIO SOCIAL DE LA CIUDAD DE MADRID A ALCOBENDAS (MADRID), C/ EINSTEIN, N. 8, 28108. 

 

 27/11/2009 EL ECONOMISTA - GENERAL INFORMATION

EL GRUPO SUANFARMA PRESENTO EL 26/11/09 SU NUEVO CENTRO DE EMPRENDIMIENTO E INCUBACION DE EMPRESAS EN SU SEDE DE ALCOBENDAS. ASIMISMO, LA CIA. HA PRESENTADO EL FONDO SUAN BIOTECH II, DE LA GESTORA SUANFARMA BIOTECH SGECR. ESTE NUEVO FONDO TIENE COMO OBJETIVO LA COTA DE LOS 30 MM. DE EUROS, QUE SE INVERTIRAN EN PROYECTOS DE BIOTECNOLOGIA Y APLICACION A LA BIOMEDICINA Y LA FARMACIA. LA INTENCION ES INVERTIR EN ENTRE 10 Y 15 PROYECTOS QUE CUMPLAN LOS REQUISITOS DE ESTAR DESARROLLADOS EN ESPAÑA Y BASDOS EN CIENCIA GENERADA EN NUESTRO PAIS, CON UNA PERMANENCIA DE ENTRE CUATRO Y CINCO AÑOS EN CADA PROYECTO. 

 

 19/09/2007 EXPANSIÓN - SHAREHOLDERS AND HOLDINGS

SUAN FARMA Y UN GRUPO DE EJECUTIVOS DEL SECTOR FARMACEUTICO Y FINANCIERO HAN PUESTO EN MARCHA EN ESPAÑA SUANFARMA BIOTECH, UNA GESTORA DE FONDOS DE CAPITAL RIESGO DEDICADOS A LA BIOTECNOLOGIA. LA NUEVA GESTORA NACE JUNTO A UN PRIMER FONDO DE CAPITAL RIESGO QUE ASPIRA A ESTAR DOTADO CON 30 MM. DE EUROS. LA INICIATIVA CUENTA CON EL COMPROMISO DE SOCIEDAD DE DESARROLLO DE NAVARRA (SODENA) Y CAPITAL RIESGO DE LA COMUNIDAD DE MADRID (QUE PREVEN INVERTIR TRES Y UN MILLON DE EUROS, RESPECTIVAMENTE) Y DE SUAN FARMA, QUE APORTA UN MILLON DE EUROS. SUANFARMA BIOTECH TIENE SELECCIONADOS SIETE PROYECTOS EMPRESARIALES Y OTROS DIEZ EN ESTUDIO. 

 

 30/06/2007 EXPANSIÓN - SHAREHOLDERS AND HOLDINGS

LA SDAD. PARA EL DESARROLLO DE NAVARRA (SODENA) HA ENTRADO COMO SOCIO PROMOTOR, CON UN 24% DE LAS ACCIONES, EN LA CIA 3P BIOPHARMACEUTICALS, PROYECTO EMPRESARIAL ENFOCADO A CREAR LA PRIMERA PLANTA EN ESPAÑA DE PRODUCCION DE PROTEINAS TERAPEUTICAS PARA LABORATORIOS Y EMPRESAS FARMACEUTICAS. LA COMPOSICION DEL ACCIONARIADO DE 3P BIOPHARMACEUTICALS QUEDA CONFORMADO POR SODENA (24%), LOS SOCIOS TECNOLOGICOS (SUAN FARMA, IDIFARMA Y DRO BIOSYSTEMS) CON EL 31,4% Y LOS SOCIOS FINANCIEROS, ENTRE ELLOS CAJA NAVARRA, CAJA RURAL DE NAVARRA Y UNIVERSIDAD DE NAVARRA, CON EL 45% RESTANTE. EL PLAN DE NEGOCIO DE LA NUEVA PLANTA CONTEMPLA UNA INVERSION DE 9 MM. PARA LOS PRIMEROS AÑOS. 

 

There are 14 press articles registered for this company

 

Complementary Information

 

Financial Information

Por causas ajenas a nuestra voluntad el Depósito de cuentas del ejercicio 2008 , se ha recibido erróneamente, teniendo disponible el Deposito Consolidado de esta.

El balance cerrado a 31/12/2003 (Depósito 2003) está disponible en INFORMA, pero no ha sido cargado por presentar en sus cuentas la siguiente anomalía: toda la información del Balance y de la cuenta de Pérdidas y Ganancias presenta errores en sus datos.

 

 

FINANCIAL INFORMATION

  

The information on the last account contained in this report is extracted from the Mercantile Register file of the legal address of the Company and dated 22/12/2010.

 

The shaded amounts in the following financial statements have been converted to the norms established in the PGC2007 derived from RD 1514/2007 and 1515/2007, this way comparatives could be shown with the amounts of exercises initiated from 1/01/08.

 

 This theoretical conversion exercise has been carried out from the financial statements contained in the accounting information presented on the Trade Register, and elaborated under the accounting norms and principles collected in PGC90 derived from RD 1643/1990, not taking into account any other type of information; for this reason the conversion exercise could include certain inaccuracies.

 

SITUATION BALANCE-SHEET

 

Assets

Figures given in €

 

31/12/2009

(12)

 

%

ASSETS

 

31/12/2008

(12)

 

%

ASSETS

 

31/12/2007

(12)

 

%

ASSETS

 

A) NON CURRENT ASSETS

8.675.293,00

37,79

5.659.138,00

29,30

5.221.652,16

28,51

I. Intangible assets

 

 

 

 

0,00

0,00

II. Tangible fixed assets

5.086.405,00

22,16

1.781.371,00

9,22

1.729.471,37

9,44

1. Property, plant and equipment

4.840.960,00

21,09

966.893,00

5,01

 

 

2. Technical fittings and other tangible assets

245.445,00

1,07

40.151,00

0,21

 

 

3. Fixed assets in progress and advances

 

 

774.327,00

4,01

 

 

III. Real-estate investments

 

 

 

 

 

 

IV. Long term investments in associated and affiliated companies

2.383.507,00

10,38

2.784.038,00

14,41

3.483.693,27

19,02

1. Net worth instruments

1.808.507,00

7,88

1.895.108,00

9,81

  

3.483.693,27

19,02

2. Credits to companies

575.000,00

2,50

888.930,00

4,60

 

 

V. Long Term Financial Investments

1.177.684,00

5,13

1.025.045,00

5,31

8.487,52

0,05

1. Net worth instruments

1.039.468,00

4,53

938.237,00

4,86

 

 

5. Other financial assets

22.146,00

0,10

2.088,00

0,01

  

8.487,52

0,05

6. Other investments

116.070,00

0,51

84.720,00

0,44

 

 

VI. Assets by deferred taxes

27.697,00

0,12

68.684,00

0,36

 

 

VII. Non current commercial debts

 

 

 

 

 

 

B) CURRENT ASSETS

14.278.852,00

62,21

13.657.458,00

70,70

13.093.359,46

71,49

I. Non-current assets maintained for sale

 

 

 

 

 

 

II. Stocks

4.202.462,00

18,31

3.045.344,00

15,77

2.448.279,86

13,37

1. Goods available for sale

4.201.521,00

18,30

2.968.904,00

15,37

 

 

6. Pre-payments to suppliers

941,00

0,00

76.440,00

0,40

 

 

III. Trade Debtors and other receivable accounts

9.708.629,00

42,30

10.036.330,00

51,96

9.933.331,51

54,24

1. Clients

8.939.654,00

38,95

9.609.405,00

49,75

 

8.806.561,62

48,08

   b) Clients for sales and short term services rendering

8.939.654,00

38,95

9.609.405,00

49,75

 

 

2. Clients group and associated companies

114.928,00

0,50

103.400,00

0,54

 

7.349,93

0,04

3. Other debts

225.282,00

0,98

48.717,00

0,25

 

885.422,97

4,83

4. Staff

3.131,00

0,01

6.631,00

0,03

 

57.335,00

0,31

5. Assets by current taxes

54.838,00

0,24

56.233,00

0,29

 

 

6. Other credits with the Public Administrations

370.796,00

1,62

211.944,00

1,10

 

176.661,99

0,96

IV. Short term investments in associated and affiliated companies

 

 

 

 

 

 

V. Short term financial investments

42.000,00

0,18

 

 

 

 

5. Other financial assets

42.000,00

0,18

 

 

 

 

VI. Short term periodifications

 

 

 

 

 

 

VII. Cash and equivalents

325.761,00

1,42

575.784,00

2,98

711.748,09

3,89

1. Treasury

325.761,00

1,42

575.784,00

2,98

711.748,09

3,89

TOTAL ASSETS (A + B)

22.954.145,00

100,00

19.316.596,00

100,00

18.315.011,62

100,00

 

Alerts associated to the conversion to PGC2007

 

 The valuation norms applicable to financial instruments has changed substantially and, for this reason the conversion of financial statements from PGC90 to PGC2007 could include notable inaccuracy.

 


 In the conversion process there has been estimated that the total item 124080 “Provisions” according to PGC90 is associated to “Net Worth Instruments”.

 

 In the conversion process there has been estimated that the total item 143070 “Provisions on debtors” according to PGC90, for %1, is associated to “Clients for sales and services rendering”.

  

Net Worth and Liabilities

Figures given in €

 

31/12/2009

(12)

 

%

ASSETS

 

31/12/2008

(12)

 

%

ASSETS

 

31/12/2007

(12)

 

%

ASSETS

 

A) NET WORTH

3.383.852,00

14,74

3.472.700,00

17,98

3.804.649,79

20,77

A-1) Equity

3.383.852,00

14,74

3.472.700,00

17,98

3.804.649,79

20,77

I. Capital

1.000.050,00

4,36

1.000.050,00

5,18

1.000.050,07

5,46

1. Authorized capital

1.000.050,00

4,36

1.000.050,00

5,18

1.000.050,07

5,46

II. Issue premium

 

 

 

 

 

 

III. Reserves

2.216.871,00

9,66

2.106.917,00

10,91

2.348.996,46

12,83

1. Legal and statutory

200.010,00

0,87

200.010,00

1,04

200.010,01

1,09

2. Other funds

2.016.861,00

8,79

1.906.907,00

9,87

2.148.986,45

11,73

IV. (Net worth own shares and participations)

 

 

 

 

 

 

V. Results from previous years

 

 

 

 

 

 

VI. Other loans from partners

 

 

 

 

 

 

VII. Exercise Result

366.931,00

1,60

565.733,00

2,93

455.603,26

2,49

VIII. (Interim dividend)

-200.000,00

-0,87

-200.000,00

-1,04

 

 

IX. Other net worth instruments

 

 

 

 

 

 

A-2) Value changes adjustments

 

 

 

 

 

 

I. Financial assets available for sale

 

 

 

 

 

 

II. Coverage operations

 

 

 

 

 

 

III. Non-current assets and related liabilities, maintained for sale

 

 

 

 

 

 

IV. Conversion differences

 

 

 

 

 

 

V. Other

 

 

 

 

 

 

A-3) Received legacies, grants and subventions

 

 

 

 

 

 

B) NON CURRENT LIABILITIES

4.943.622,00

21,54

1.980.433,00

10,25

2.782.714,60

15,19

I. Long term provisions

306.070,00

1,33

84.720,00

0,44

58.108,50

0,32

1. Long term staff benefits obligations

116.070,00

0,51

84.720,00

0,44

58.108,50

0,32

4. Other provisions

190.000,00

0,83

 

 

 

 

II. Long term debts

4.545.499,00

19,80

1.895.713,00

9,81

2.724.606,10

14,88

2. Debts with bank entities

4.433.775,00

19,32

1.895.713,00

9,81

2.724.606,10

14,88

3. Financial leasing creditors

111.724,00

0,49

 

 

 

 

III. Long term debts with associated and affiliated companies

 

 

 

 

 

 

IV. Liabilities by deferred taxes

92.053,00

0,40

 

 

 

 

V. Long term periodifications

 

 

 

 

 

 

VI. Non current trade creditors

 

 

 

 

 

 

VII. Long term debts with special characteristics

 

 

 

 

 

 

C) CURRENT LIABILITIES

14.626.671,00

63,72

13.863.463,00

71,77

11.727.647,23

64,03

I. Liabilities related with non-current assets maintained for sale

 

 

 

 

 

 

II. Short term provisions

 

 

 

 

 

 

III. Short term debts

6.420.505,00

27,97

5.053.882,00

26,16

4.117.233,15

22,48

2. Debts with bank entities

6.382.768,00

27,81

5.053.882,00

26,16

4.117.233,15

22,48

3. Financial leasing creditors

27.187,00

0,12

 

 

 

 

5. Other financial liabilities

10.550,00

0,05

 

 

 

 

IV. Short term debts with associated and affiliated companies

 

 

 

 

 

 

V. Trade creditors and other payable accounts

8.206.166,00

35,75

8.809.581,00

45,61

7.610.414,08

41,55

1. Suppliers

6.108.100,00

26,61

6.728.667,00

34,83

6.948.978,67

37,94

   b) Short term suppliers

6.108.100,00

26,61

6.728.667,00

34,83

 

 

2. Suppliers group and associated companies

430.901,00

1,88

124.422,00

0,64

 

 

3. Different creditors

1.295.933,00

5,65

1.261.402,00

6,53

 

 

4. Staff (pending remunerations)

276.993,00

1,21

563.098,00

2,92

572.753,59

3,13

6. Other debts with Public Administrations

93.838,00

0,41

131.590,00

0,68

 

87.928,25

0,48

7. Clients pre-payments

401,00

0,00

402,00

0,00

753,57

0,00

VI. Short term periodifications

 

 

 

 

 

 

VII. Short term debts with special characteristics

 

 

 

 

 

 

TOTAL NET WORTH AND LIABILITIES (A + B + C)

22.954.145,00

100,00

19.316.596,00

100,00

18.315.011,62

100,00

 

Alerts associated to the conversion to PGC2007

 

 In the conversion process it has not been possible to breakdown the composition of liabilities originated by debts with the public administrations; for this reason the mentioned amounts are presented fully aggregated in the item “other debts with the public administrations”

 

 

PROFIT AND LOSS ACCOUNT

Figures given in €

 

31/12/2009

(12)

 

%ING.

EXPLOT.

 

31/12/2008

(12)

 

%ING.

EXPLOT.

 

31/12/2007

(12)

 

%ING.

EXPLOT.

 

A) CONTINUED OPERATIONS

 

 

 

 

 

 

1. Net Turnover

36.236.485,00

99,79

33.234.919,00

99,55

33.938.992,32

99,56

A) Sales

35.751.710,00

98,46

32.951.202,00

98,70

33.691.374,48

98,83

b) Services provided

484.775,00

1,34

283.717,00

0,85

247.617,84

0,73

2. Variation in stocks of finished goods and work in progress

 

 

 

 

 

 

3. Works for its own assets

 

 

 

 

 

 

4. Supplies

-29.759.805,00

-81,96

-26.656.888,00

-79,85

-27.845.647,86

-81,69

a) Material consumed

-29.663.676,00

-81,69

-26.670.454,00

-79,89

-27.746.867,82

-81,40

b) Raw materials consumed

-9.855,00

-0,03

-11.768,00

-0,04

-1.551,68

0,00

c) Works carried out for other companies

-93.034,00

-0,26

-20.995,00

-0,06

-61.856,36

-0,18

d) Deterioration on merchandises, raw materials and other supplies

6.760,00

0,02

46.329,00

0,14

-35.372,00

-0,10

5. Other operating income

75.042,00

0,21

149.592,00

0,45

149.649,56

0,44

a) Other incomes

14.018,00

0,04

 

 

101.330,27

0,30

b) Operating grants included in the exercise result

61.024,00

0,17

149.592,00

0,45

48.319,29

0,14

6. Labour cost

-2.408.632,00

-6,63

-2.520.799,00

-7,55

-3.348.234,17

-9,82

a) Wages and similar expenses

-1.968.080,00

-5,42

-2.141.360,00

-6,41

 

 

b) Social costs

-440.552,00

-1,21

-379.439,00

-1,14

 

 

7. Other operating costs

-3.619.862,00

-9,97

-3.531.145,00

-10,58

-2.478.150,57

-7,27

a) External services

-3.596.080,00

-9,90

-3.555.911,00

-10,65

-2.429.618,80

-7,13

b) Taxes

-19.130,00

-0,05

-24.344,00

-0,07

-6.014,82

-0,02

c) Losses, deterioration and variation on business operations provisions

-4.652,00

-0,01

49.110,00

0,15

-35.907,00

-0,11

d) Other day to day expenses

 

 

 

 

-6.609,95

-0,02

8. Amortization of fixed assets

-21.953,00

-0,06

-22.479,00

-0,07

-48.691,14

-0,14

9. Allocation of subventions on non financial investments and other

 

 

 

 

 

 

10. Provisions excess

 

 

 

 

 

 

11. Deterioration and result for fixed assets disposal

 

 

-59.979,00

-0,18

-47.039,00

-0,14

a) Deteriorations and losses

 

 

 

 

-47.039,00

-0,14

b) Results for disposals and others

 

 

-59.979,00

-0,18

 

 

12. Negative difference of business combinations

 

 

 

 

 

 

13. Other results

-161.428,00

-0,44

10.639,00

0,03

 

 

A.1) OPERATING RESULT (1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10 + 11 + 12 + 13)

339.847,00

0,94

603.860,00

1,81

320.879,14

0,94

14. Financial income

7.382,00

0,02

132.899,00

0,40

14.561,02

0,04

a) From net worth instruments participations

7.382,00

0,02

132.899,00

0,40

 

 

   a 1) On group and associated companies

 

 

103.872,00

0,31

 

 

   a 2) On third parties

7.382,00

0,02

29.027,00

0,09

 

 

b) From negotiable values and other financial instruments

 

 

 

 

14.561,02

0,04

   b 2) From third parties

 

 

 

 

14.561,02

0,04

15. Financial expenses

-103.895,00

-0,29

-225.701,00

-0,68

-211.739,04

-0,62

a) For debts with associated and affiliated companies

 

 

 

 

-209.669,28

-0,62

b) For debts with third parties

-103.895,00

-0,29

-225.701,00

-0,68

-2.069,76

-0,01

16. Reasonable value variation on financial instruments

60.014,00

0,17

 

 

 

 

a) Negotiation portfolio and others

60.014,00

0,17

 

 

 

 

17. Exchange differences

160.580,00

0,44

-117.239,00

-0,35

455.795,54

1,34

18. Deterioration and result for disposal of financial instruments

-15.864,00

-0,04

244.125,00

0,73

 

 

a) Deteriorations and losses

-15.864,00

-0,04

-596.638,00

-1,79

 

 

b) Results for disposals and others

 

 

840.763,00

2,52

 

 

19. Other financial income and expenses

 

 

 

 

 

 

A.2) FINANCIAL RESULT (14 + 15 + 16 + 17 + 18 + 19)

108.217,00

0,30

34.084,00

0,10

 

258.617,52

0,76

A.3) RESULT BEFORE TAXES (A.1 + A.2)

448.064,00

1,23

637.944,00

1,91

579.496,66

1,70

20. Taxes on profits

-81.133,00

-0,22

-72.211,00

-0,22

-123.893,40

-0,36

A.4) EXERCISE RESULT COMING FROM CONTINUED OPERATIONS (A.3 + 20)

366.931,00

1,01

565.733,00

1,69

455.603,26

1,34

B) DISCONTINUED OPERATIONS

 

 

 

 

 

 

21. Net of taxes exercise result coming from discontinued operations

 

 

 

 

 

 

A.5) EXERCISE RESULT (A.4 + 21)

366.931,00

1,01

565.733,00

1,69

455.603,26

1,34

 

Alerts associated to the conversion to PGC2007

 

 Valuation norms applicable to Financial instruments collected in PGC2007 present notable changes with respect to PGC90. As a consequence, the conversion of the financial statements of the accounts to PGC2007, carried out considering mainly classification changes in the accounts might contain certain inaccuracies.


NET WORTH CHANGES STATUS

  

Status of recognized income and expenses

Figures given in €

NET WORTH CHANGES (1/3)

31/12/2009

(12)

 

31/12/2008

(12)

 

A) PROFIT AND LOSS ACCOUNT RESULT

366.931,00

565.733,00

INCOME AND EXPENSES ALLOCATED DIRECTLY TO NET WORTH

 

 

I. For valuation of financial instruments

 

 

II. Cash flow coverage

 

 

III. Received legacies, grants and subventions

 

 

IV. For actuarial profits and losses and other adjustments

 

 

V. Non-current assets and related liabilities, maintained for sale

 

 

VI. Conversion differences

 

 

VII. Tax effect

 

 

B) TOTAL INCOME AND EXPENSES ALLOCATED DIRECTLY TO NET WORTH (I + II + III + IV +V+VI+VII)

 

 

PROFIT AND LOSS ACCOUNT TRANSFERS

 

 

VIII. For valuation of financial instruments

 

 

IX. Cash flow coverage

 

 

X. Received legacies, grants and subventions

 

 

XI. Non-current assets and related liabilities, maintained for sale

 

 

XII. Conversion differences

 

 

XIII. Tax effect

 

 

C) TOTAL TRANSFERS TO THE PROFIT AND LOSS ACCOUNT (VIII + IX + X + XI+ XII+ XIII)

 

 

TOTAL INCOME AND EXPENSES RECOGNIZED (A + B + C)

366.931,00

565.733,00

 

Total net worth changes status

Figures given in €

NET WORTH CHANGES ( 2 /3)

AUTHORIZED CAPITAL

RESERVES

EXERCISE RESULT

(INTERIM DIVIDEND)

FINAL ACCOUNT BALANCE OF EXERCISE (2007)

1.000.050,00

2.348.996,00

357.921,00

 

I. Adjustments by change of criteria in the exercise (2007)

 

 

 

 

II. Adjustments by errors in the exercise (2007)

 

 

 

 

ADJUSTED ACCOUNT BALANCE, BEGINNING OF EXERCISE (2008)

1.000.050,00

2.348.996,00

357.921,00

 

I. Total recognized income and expenses

 

 

565.733,00

 

II. Operations with partners or owners

 

-600.000,00

 

-200.000,00

4. (-) Dividends distribution

 

-600.000,00

 

-200.000,00

III. Other net worth variations

 

357.921,00

-357.921,00

 

FINAL ACCOUNT BALANCE OF EXERCISE (2008)

1.000.050,00

2.106.917,00

565.733,00

-200.000,00

I. Adjustments by change of criteria in the exercise (2008)

 

 

 

 

II. Adjustments by errors in the exercise (2008)

 

 

-121.119,00

 

ADJUSTED ACCOUNT BALANCE, BEGINNING OF EXERCISE (2009)

1.000.050,00

2.106.917,00

444.614,00

-200.000,00

I. Total recognized income and expenses

 

 

366.931,00

 

II. Operations with partners or owners

 

 

-300.000,00

 

4. (-) Dividends distribution

 

 

-300.000,00

 

III. Other net worth variations

 

109.954,00

-144.614,00

 

FINAL ACCOUNT BALANCE OF EXERCISE (2009)

1.000.050,00

2.216.871,00

366.931,00

-200.000,00

NET WORTH CHANGES ( 3 /3)

TOTAL

 

FINAL ACCOUNT BALANCE OF EXERCISE (2007)

3.706.967,00

 

I. Adjustments by change of criteria in the exercise (2007)

 

 

II. Adjustments by errors in the exercise (2007)

 

 

ADJUSTED ACCOUNT BALANCE, BEGINNING OF EXERCISE (2008)

3.706.967,00

 

I. Total recognized income and expenses

565.733,00

 

II. Operations with partners or owners

-800.000,00

 

4. (-) Dividends distribution

-800.000,00

 

III. Other net worth variations

 

 

FINAL ACCOUNT BALANCE OF EXERCISE (2008)

3.472.700,00

 

I. Adjustments by change of criteria in the exercise (2008)

 

 

II. Adjustments by errors in the exercise (2008)

-121.119,00

 

ADJUSTED ACCOUNT BALANCE, BEGINNING OF EXERCISE (2009)

3.351.581,00

 

I. Total recognized income and expenses

366.931,00

 

II. Operations with partners or owners

-300.000,00

 

4. (-) Dividends distribution

-300.000,00

 

III. Other net worth variations

-34.660,00

 

FINAL ACCOUNT BALANCE OF EXERCISE (2009)

3.383.852,00

 

 

 

CASH FLOW STATUS

Figures given in €

 

31/12/2009

(12)

 

31/12/2008

(12)

 

A) CASH FLOW COMING FROM OPERATING ACTIVITIES

 

 

1. exercise result before taxes

448.064,00

637.944,00

2. Results adjustments

257.556,00

-88.468,00

a) Amortization of fixed assets (+)

21.953,00

22.479,00

b) Value correction for deterioration (+/-)

9.104,00

 

e) Results for decline and disposal of fixed assets (+/-)

 

-184.146,00

g) Financial income (-)

-7.382,00

-132.899,00

f) Financial expenses (+)

103.895,00

209.574,00

j) Reasonable value variation on financial instruments (+/-)

-60.014,00

 

k) Other income and expenses (-/+)

190.000,00

-3.476,00

3. Changes in current capital

-728.902,00

-623.115,00

a) Stocks (+/-)

-1.150.359,00

-597.064,00

b) Debtors and other receivable accounts (+/-)

330.097,00

-1.216.763,00

c) Other current assets (+/-)

-42.000,00

 

d) Creditors and other payable accounts (+/-)

-605.810,00

1.190.712,00

e) Other current liabilities (+/-)

739.170,00

 

4. Other cash flow coming from operating activities

-84.179,00

-255.433,00

a) Interests payments (-)

-91.561,00

-225.701,00

c) Interests collections (+)

7.382,00

29.027,00

d) Collections (payments) for profit tax (+/-)

 

-75.153,00

e) Other payments (collections) (-/+)

 

16.394,00

5. Cash flow coming from operating activities (1 + 2 + 3 + 4)

-107.461,00

-329.072,00

B) CASH FLOW COMING FROM INVESTING ACTIVITIES

 

 

6. Investment payments (-)

-3.410.651,00

-737.476,00

a) Group and associated companies

 

-78.000,00

c) Tangible assets

-3.360.171,00

-557.876,00

e) Other financial assets

-50.480,00

-101.600,00

7. Disinvestment collections (+)

270.000,00

1.711.441,00

c) Tangible assets

 

645.258,00

e) Other financial assets

270.000,00

1.066.183,00

8. Cash Flow in investment activities (6 + 7)

-3.140.651,00

973.965,00

C) CASH FLOW COMING FROM FINANCING ACTIVITIES

 

 

9. Net worth instruments collections and payments

 

 

10. Financial liabilities instruments collections and payments

3.298.089,00

19.143,00

a) Issue

3.699.941,00

500.000,00

   2. Debts with bank entities (+)

3.699.941,00

500.000,00

b) Return and amortization of

-401.852,00

-480.857,00

   2. Debts with bank entities (-)

-401.852,00

-480.857,00

11. Payments for dividends and remunerations of other net worth instruments

-300.000,00

-800.000,00

a) Dividends (-)

-300.000,00

-800.000,00

12. Cash Flow in financing activities (9 + 10 + 11)

2.998.089,00

-780.857,00

D) Exchange rate variations effect

 

 

E) NET CASH OR EQUIVALENTS INCREASE / REDUCTION (5 + 8 + 12 + D)

-250.023,00

-135.964,00

Cash or equivalents at the beginning of the exercise

575.784,00

711.748,00

Cash or equivalents at the end of the exercise

325.761,00

575.784,00

 

 

RATIOS

 

 

31/12/2009

(12)

 

CHANGE %

31/12/2008

(12)

 

CHANGE %

31/12/2007

(12)

 

BALANCE RATIOS

Working Capital (€)

-347.819,00

-68,84

-206.005,00

-115,08

1.365.712,23

Working capital ratio

-0,02

0,00

-0,01

-112,50

0,08

Soundness Ratio

0,39

-36,07

0,61

-16,44

0,73

Average Collection Period (days)

96

-11,26

109

3,07

105

Average Payment Period (days)

89

-15,75

105

16,33

90

LIQUIDITY RATIOS

Current Ratio (%)

97,62

-0,90

98,51

-11,77

111,64

Quick Ratio (%)

2,51

-39,52

4,15

-31,63

6,07

DEBT RATIOS

Borrowing percentage (%)

47,77

32,77

35,98

-3,69

37,36

External Financing Average Cost

0,01

-66,67

0,03

0,00

0,03

Debt Service Coverage

-102,05

-383,19

-21,12

-255,64

13,57

Interest Coverage

3,27

22,01

2,68

76,32

1,52

GENERAL AND ACTIVITIES RATIOS

Auto financing generated by sales (%)

-0,30

69,70

-0,99

-166,44

1,49

Auto financing generated by Assets (%)

-0,47

72,35

-1,70

-161,82

2,75

Breakdown Point

1,01

-0,98

1,02

0,99

1,01

Average Sales Volume per Employee

1.132.390,16

-8,00

1.230.922,93

16,06

1.060.593,51

Average Cost per Employee

75.269,75

-19,38

93.362,93

-10,77

104.632,32

Assets Turnover

1,58

-8,14

1,72

-7,03

1,85

Inventory Turnover (days)

51

23,68

41

29,55

32

RESULTS RATIOS

Return on Assets (ROA) (%)

1,48

-52,72

3,13

78,86

1,75

Operating Profitability (%)

1,58

-46,08

2,93

66,48

1,76

Return on Equity (ROE) (%)

13,24

-27,93

18,37

20,62

15,23

 

 

SECTORIAL ANALYSIS 

 

Balance Sheet and Financial Balance

Figures expressed in %

 

COMPANY

(2009)

 

SECTOR

DIFFERENCE

BALANCE SHEET ANALYSIS: % on the total assets

 

 

 

ASSETS

A) NON CURRENT ASSETS

37,79

22,56

15,24

A) CURRENT ASSETS

62,21

77,44

-15,24

LIABILITIES

A) NET WORTH

14,74

41,22

-26,48

B) NON CURRENT LIABILITIES

21,54

8,37

13,17

C) CURRENT LIABILITIES

63,72

50,42

13,31

 

 

 

 

 

Analytical Account of Results

Figures given in  %

 

COMPANY

(2009)

 

SECTOR

 

DIFFERENCE

 

Net Turnover

99,79

98,58

1,21

Other operating income

0,21

1,42

-1,21

OPERATING INCOME

100,00

100,00

0,00

Supplies

-81,96

-65,34

-16,62

Variation in stocks of finished goods and work in progress

 

0,17

 

GROSS MARGIN

18,04

34,83

-16,79

Other operating costs

-9,97

-14,32

4,35

Labour cost

-6,63

-14,25

7,62

GROSS OPERATING RESULT

1,44

6,26

-4,82

Amortization of fixed assets

-0,06

-1,42

1,36

Deterioration and result for fixed assets disposal

 

0,03

 

Other expenses / income

-0,44

 

 

NET OPERATING RESULT

0,94

4,87

-3,93

Financial result

0,30

0,11

0,19

RESULT BEFORE TAX

1,23

4,98

-3,75

Taxes on profits

-0,22

-1,39

1,17

RESULT COMING FROM CONTINUED OPERATIONS

1,01

 

 

NET RESULT

1,01

3,59

-2,58

 

Main Ratios

 

 

COMPANY

(2009)

 

PTILE25

 

PTILE50

 

PTILE75

 

BALANCE RATIOS

 

 

 

 

Working Capital (€)

-347.819,00

853.522,48

1.896.586,35

3.658.494,87

Working capital ratio

-0,02

0,12

0,31

0,46

Soundness Ratio

0,39

1,20

4,03

10,42

Average Collection Period (days)

96

57

93

164

Average Payment Period (days)

89

11

33

73

LIQUIDITY RATIOS

 

 

 

 

Current Ratio (%)

97,62

1,18

1,57

2,07

Quick Ratio (%)

2,51

0,02

0,09

0,38

DEBT RATIOS

 

 

 

 

Borrowing percentage (%)

47,77

3,45

23,96

44,64

External Financing Average Cost

0,01

0,01

0,05

0,08

Debt Service Coverage

-102,05

0,17

2,30

8,43

Interest Coverage

3,27

1,87

5,35

29,81

GENERAL AND ACTIVITIES RATIOS

 

 

 

 

Auto financing generated by sales (%)

-0,30

1,29

2,93

6,56

Auto financing generated by Assets (%)

-0,47

2,64

6,61

11,13

Breakdown Point

1,01

1,01

1,03

1,08

Average Sales Volume per Employee

1.132.390,16

198.178,09

389.295,59

721.288,34

Average Cost per Employee

75.269,75

31.274,37

34.489,86

50.816,98

Assets Turnover

1,58

1,18

1,78

2,53

Inventory Turnover (days)

51

31

56

108

RESULTS RATIOS

 

 

 

 

Return on Assets (ROA) (%)

1,48

2,66

6,67

12,53

Operating Profitability (%)

1,58

4,90

9,54

15,31

Return on Equity (ROE) (%)

13,24

5,84

19,30

32,85

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.45.20

UK Pound

1

Rs.73.17

Euro

1

Rs.61.88

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.